Free Trial

Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Rhythm Pharmaceuticals logo
$100.23 +0.40 (+0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$100.19 -0.04 (-0.04%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)

Advanced

Key Stats

Today's Range
$99.06
$100.91
50-Day Range
$84.66
$104.57
52-Week Range
$45.90
$106.52
Volume
428,145 shs
Average Volume
656,252 shs
Market Capitalization
$6.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$106.64
Consensus Rating
Moderate Buy

Company Overview

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
71st Percentile Overall Score

RYTM MarketRank™: 

Rhythm Pharmaceuticals scored higher than 71% of companies evaluated by MarketBeat, and ranked 292nd out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 15 buy ratings, no hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Rhythm Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Rhythm Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Rhythm Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rhythm Pharmaceuticals is -33.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rhythm Pharmaceuticals is -33.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rhythm Pharmaceuticals has a P/B Ratio of 286.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Rhythm Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    7.86% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Rhythm Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rhythm Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.86% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 7.2.
  • Change versus previous month

    Short interest in Rhythm Pharmaceuticals has recently increased by 5.03%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Rhythm Pharmaceuticals has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Rhythm Pharmaceuticals this week, compared to 9 articles on an average week.
  • Search Interest

    4 people have searched for RYTM on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,274,593.00 in company stock.

  • Percentage Held by Insiders

    Only 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

  • Read more about Rhythm Pharmaceuticals' insider trading history.
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RYTM Stock News Headlines

Bitcoin hits $125K… but the real story is hiding elsewhere
A cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a full FPV ecosystem — training troops, supporting operations overseas, and expanding America’s battlefield tech edge.tc pixel
See More Headlines

RYTM Stock Analysis - Frequently Asked Questions

Rhythm Pharmaceuticals' stock was trading at $55.98 at the beginning of the year. Since then, RYTM shares have increased by 79.0% and is now trading at $100.23.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings data on Tuesday, August, 5th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.09. Rhythm Pharmaceuticals's revenue was up 66.8% on a year-over-year basis.
Read the conference call transcript
.

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.34%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, Joseph Shulman, William T Roberts, Jennifer Kayden Lee, Jennifer Chien, Alastair Garfield, Lynn A Tetrault, Jennifer L Good and Christopher Paul German.
View institutional ownership trends
.

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/05/2025
Today
10/08/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RYTM
CIK
1649904
Employees
140
Year Founded
2008

Price Target and Rating

High Price Target
$142.00
Low Price Target
$65.00
Potential Upside/Downside
+6.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$260.60 million
Net Margins
-117.13%
Pretax Margin
-117.17%
Return on Equity
-1,831.43%
Return on Assets
-48.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.79
Quick Ratio
2.64

Sales & Book Value

Annual Sales
$130.13 million
Price / Sales
51.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
285.53

Miscellaneous

Outstanding Shares
66,420,000
Free Float
62,368,000
Market Cap
$6.64 billion
Optionable
Optionable
Beta
2.12

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:RYTM) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners